Home » AVI BIOPHARMA GAINS PATENTS COVERING PRESERVATION, EXPANSION OF STEM CELLS USING NEUGENE ANTISENSE AGENTS
AVI BIOPHARMA GAINS PATENTS COVERING PRESERVATION, EXPANSION OF STEM CELLS USING NEUGENE ANTISENSE AGENTS
AVI BioPharma has been issued a U.S. patent and notice of allowance on another patent, covering the use of antisense to modulate stem-cell maturation.
AVI's third-generation NEUGENE antisense agents, which target transforming growth factor beta (TGF-beta) and other gene targets, have been shown to program stem cells in culture for long-term survival after implantation.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct